These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 17293013

  • 1. Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.
    Zeng M, Xu Q, Pichichero ME.
    Vaccine; 2007 May 04; 25(18):3588-94. PubMed ID: 17293013
    [Abstract] [Full Text] [Related]

  • 2. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge.
    Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, Peterson JW, Baker JR.
    Infect Immun; 2007 Aug 04; 75(8):4020-9. PubMed ID: 17502384
    [Abstract] [Full Text] [Related]

  • 3. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities.
    Sloat BR, Cui Z.
    Pharm Res; 2006 Jun 04; 23(6):1217-26. PubMed ID: 16718616
    [Abstract] [Full Text] [Related]

  • 4. A plant based protective antigen [PA(dIV)] vaccine expressed in chloroplasts demonstrates protective immunity in mice against anthrax.
    Gorantala J, Grover S, Goel D, Rahi A, Jayadev Magani SK, Chandra S, Bhatnagar R.
    Vaccine; 2011 Jun 15; 29(27):4521-33. PubMed ID: 21504775
    [Abstract] [Full Text] [Related]

  • 5. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
    Boyaka PN, Tafaro A, Fischer R, Leppla SH, Fujihashi K, McGhee JR.
    J Immunol; 2003 Jun 01; 170(11):5636-43. PubMed ID: 12759444
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthrax.
    Gauthier YP, Tournier JN, Paucod JC, Corre JP, Mock M, Goossens PL, Vidal DR.
    Infect Immun; 2009 Mar 01; 77(3):1197-207. PubMed ID: 19114543
    [Abstract] [Full Text] [Related]

  • 7. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin.
    Gaur R, Gupta PK, Banerjea AC, Singh Y.
    Vaccine; 2002 Jun 21; 20(21-22):2836-9. PubMed ID: 12034111
    [Abstract] [Full Text] [Related]

  • 8. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits.
    Wimer-Mackin S, Hinchcliffe M, Petrie CR, Warwood SJ, Tino WT, Williams MS, Stenz JP, Cheff A, Richardson C.
    Vaccine; 2006 May 01; 24(18):3953-63. PubMed ID: 16530302
    [Abstract] [Full Text] [Related]

  • 9. Detoxified lethal toxin as a potential mucosal vaccine against anthrax.
    Xu Q, Zeng M.
    Clin Vaccine Immunol; 2008 Apr 01; 15(4):612-6. PubMed ID: 18256208
    [Abstract] [Full Text] [Related]

  • 10. Generation of protective immune response against anthrax by oral immunization with protective antigen plant-based vaccine.
    Gorantala J, Grover S, Rahi A, Chaudhary P, Rajwanshi R, Sarin NB, Bhatnagar R.
    J Biotechnol; 2014 Apr 20; 176():1-10. PubMed ID: 24548460
    [Abstract] [Full Text] [Related]

  • 11. A Bivalent Protein r-PAbxpB Comprising PA Domain IV and Exosporium Protein BxpB Confers Protection Against B. anthracis Spores and Toxin.
    Majumder S, Das S, Somani VK, Makam SS, Kingston JJ, Bhatnagar R.
    Front Immunol; 2019 Apr 20; 10():498. PubMed ID: 30941133
    [Abstract] [Full Text] [Related]

  • 12. Nasal immunization with a dual antigen anthrax vaccine induced strong mucosal and systemic immune responses against toxins and bacilli.
    Sloat BR, Cui Z.
    Vaccine; 2006 Sep 29; 24(40-41):6405-13. PubMed ID: 16828937
    [Abstract] [Full Text] [Related]

  • 13. Human monoclonal antibodies against anthrax lethal factor and protective antigen act independently to protect against Bacillus anthracis infection and enhance endogenous immunity to anthrax.
    Albrecht MT, Li H, Williamson ED, LeButt CS, Flick-Smith HC, Quinn CP, Westra H, Galloway D, Mateczun A, Goldman S, Groen H, Baillie LW.
    Infect Immun; 2007 Nov 29; 75(11):5425-33. PubMed ID: 17646360
    [Abstract] [Full Text] [Related]

  • 14. Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge.
    Osorio M, Wu Y, Singh S, Merkel TJ, Bhattacharyya S, Blake MS, Kopecko DJ.
    Infect Immun; 2009 Apr 29; 77(4):1475-82. PubMed ID: 19179420
    [Abstract] [Full Text] [Related]

  • 15. Towards a human oral vaccine for anthrax: the utility of a Salmonella Typhi Ty21a-based prime-boost immunization strategy.
    Baillie LW, Rodriguez AL, Moore S, Atkins HS, Feng C, Nataro JP, Pasetti MF.
    Vaccine; 2008 Nov 11; 26(48):6083-91. PubMed ID: 18805452
    [Abstract] [Full Text] [Related]

  • 16. Comparative analysis of the immunologic response induced by the Sterne 34F2 live spore Bacillus anthracis vaccine in a ruminant model.
    Ndumnego OC, Köhler SM, Crafford J, van Heerden H, Beyer W.
    Vet Immunol Immunopathol; 2016 Oct 01; 178():14-21. PubMed ID: 27496738
    [Abstract] [Full Text] [Related]

  • 17. BA3338, a surface layer homology domain possessing protein augments immune response and protection efficacy of protective antigen against Bacillus anthracis in mouse model.
    Kumar M, Puranik N, Varshney A, Tripathi N, Pal V, Goel AK.
    J Appl Microbiol; 2020 Aug 01; 129(2):443-452. PubMed ID: 32118336
    [Abstract] [Full Text] [Related]

  • 18. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
    Welkos S, Little S, Friedlander A, Fritz D, Fellows P.
    Microbiology (Reading); 2001 Jun 01; 147(Pt 6):1677-1685. PubMed ID: 11390699
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and immunogenicity of single-dose AdVAV intranasal anthrax vaccine compared to anthrax vaccine absorbed in an aerosolized spore rabbit challenge model.
    Krishnan V, Andersen BH, Shoemaker C, Sivko GS, Tordoff KP, Stark GV, Zhang J, Feng T, Duchars M, Roberts MS.
    Clin Vaccine Immunol; 2015 Apr 01; 22(4):430-9. PubMed ID: 25673303
    [Abstract] [Full Text] [Related]

  • 20. Development of a novel adjuvanted nasal vaccine: C48/80 associated with chitosan nanoparticles as a path to enhance mucosal immunity.
    Bento D, Staats HF, Gonçalves T, Borges O.
    Eur J Pharm Biopharm; 2015 Jun 01; 93():149-64. PubMed ID: 25818119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.